Novartis' (NVS.US) new 1st-class radioactive cancer therapy has been approved for clinical trials in China.

On March 3, the National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) officially announced that Novartis (NVS.US) had been approved to conduct clinical trials for its 1st-class new drug [225Ac]Ac-PSMA-617 injection, which is intended to treat metastatic hormone-resistant prostate cancer positive for PSMA after [177Lu]Lu-PSMA targeted therapy. According to Novartis' pipeline information on its website, this is a radioactive ligand therapy targeting PSMA (development code: AAA817), which has entered the 2/3 phase clinical research stage in the international market. This is the first time the product has been approved for IND in China.